According Novo Nordisk A/S"s Lars Rebien Sorensen, the diabetes treatment Victoza [liraglutide] launched on a number of European markets, has been doing well. In contrast to conventional insulin treatments the drug helps patients to lose weight while reduces the risk of pushing blood glucose dangerously low. Novo Nordisk A/S said that its second-quarter net profit rose by 21 percent assisted by insulin sales in North America. The drug"s 1.2 milligram dose price is similar to the rival drug, Byetta [exenatide] from Eli Lilly and Amylin Pharmaceutical.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지